Immunic Achieves Nasdaq Compliance

Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm known for developing novel oral therapies for neurologic diseases, has regained compliance with Nasdaq's minimum bid price requirement. On March 27, 2026, the Nasdaq Stock Market informed Immunic that it met the criteria for continued listing on the Nasdaq Capital Market.

The company's common stock closed at $1.00 per share or higher for 20 consecutive business days, meeting the Nasdaq rule 5550(a)(2) stipulation as of March 26, 2026. This adjustment closes the compliance issue.

Immunic is in the late stages of developing vidofludimus calcium for treating relapsing multiple sclerosis. The drug is in phase 3, with top-line data expected by the end of 2026. Other projects include IMU-856 and IMU-381, which target neurodegenerative and autoimmune diseases.